Dr Rachel Rau speaks to ecancer about a phase three trial she presented at ASH 2024 which shows that combining chemotherapy with blinatumomab significantly enhances disease-free survival rates in children with NCI standard risk paediatric B-ALL.

She explains that patients receiving this combination achieve a 96% survival rate compared to 87.9% with standard chemotherapy.

The addition of blinatumomab reduces bone marrow relapses and overall relapse incidents, while maintaining low toxicity levels.

Dr Rau believes that the findings suggest that blinatumomab should be adopted as a new standard treatment.